Glutathione is THE Master Detoxifier
And it’s your body’s own internal antioxidant – the main one (1).
Glutathione attaches itself to toxins, makes them easily transportable for efficient elimination in your bile and stool.
It helps proper cellular functions and enables efficient energy metabolism. It’s integral to your immune system, especially for resistance to viruses (2).
Glutathione can become depleted with chronic exposure to toxins, viral infection and other settings of increased oxidative stress (3).
Optimized Bioavailability with Liposomes
Typical oral delivery of glutathione is greatly inhibited by breakdown in the stomach. QuickSilver’s Liposomal Delivery System protects against this and dramatically enhances cellular delivery. In cell cultures, Liposomal Glutathione demonstrated to be 100 times more efficienct for intracellular delivery than non-liposomal glutathione (4).
Very small liposomes are rapidly absorbed orally and through lymphatics, and allows intracellular delivery of their encapsulated contents, leading to higher intracellular delivery than possible with intravenous (IV) therapies.
Power of Intravenous Therapy to Oral Delivery
The phospholipids delivered with Glutathione nourish your cell membranes, ensuring proper absorption of nutrients, and elimination of toxic waste.
In addition to exceptional absorption rates, these very small liposomal and nanoemulsified particles enhance lymphatic circulation of nutrients and intracellular delivery (5,6).
The phospholipids, inherent in the liposomal and nanoemulsified formats, nourish cell membranes, promoting proper function for the absorption of nutrients and the excretion of cellular waste products and toxins (7).
Improved liposomal and emulsification technology with smaller, more stable particles from the highest grade ingredients available.
- Rapid uptake
- Unparalleled bioactivity
- Extended release
- Prolonged effects.
Liposomal format absorbs through your lymph system, lessening the burden on your liver – safer for prolonged supplementation.
References
- Devasagayam TP, et al. J Assoc Physicians India. 2004 Oct;52:794-804.
- Palamara AT, et al. Antiviral Res. 1995 Jun;27(3):237-53.
- Patrick L. Altern Med Rev. 2002 Dec;7(6):456-71.
- Zeevalk GD, et al. Neurochem Res. 2010 Oct;35(10):1575-87.
- Alyautdin R, et al. Int J Nanomedicine. 2014 Feb 7;9:795-811.
- Ahn H, Park JH. Biomater Res. 2016 Nov 23;20:36.
- Spector AA, Yorek MA. J Lipid Res. 1985 Sep;26(9):1015-35.
